Jenny Zhang

发表

Model-Based Approach for Optimization of Atazanavir Dose Recommendations for HIV-Infected Pediatric Patients

K. Kowalski, R. Bertz, M. Pfister, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Pharmacodynamics of Atazanavir‐containing Antiretroviral Regimens, with or without Ritonavir, in Patients who are HIV‐positive and Treatment‐naïve

R. Bertz, D. Grasela, A. Persson, 2013, Pharmacotherapy.

Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.

R. Bertz, Yaoshi Wu, Jenny Zhang, 2011, The Journal of antimicrobial chemotherapy.

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

M. Kozal, R. Leavitt, F. Raffi, 2012, HIV clinical trials.

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.

M. Krystal, R. Bertz, A. Persson, 2012, The Journal of antimicrobial chemotherapy.

Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.

P. Tebas, M. Boffito, R. Bertz, 2011, AIDS patient care and STDs.

The Effect of Atazanavir/Ritonavir on the Pharmacokinetics of An Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Women

R. Bertz, A. Persson, T. Eley, 2011, Antiviral therapy.

Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals

R. Bertz, A. Persson, J. Butterton, 2010, Antiviral therapy.

The Effect of Efavirenz on the Pharmacokinetics of An Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy HIV-Negative Women

R. Bertz, A. Persson, T. Eley, 2011, Antiviral therapy.